NateraNASDAQ: NTRA

The headline numbers for Natera (NTRA) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Natera (NTRA) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $0.95 per share a year ago.

Natera (NTRA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced that new data from the GALAXY arm of the ongoing CIRCULATE-Japan trial was released today at the 2024 Congress of the European Society for Medical Oncology (ESMO) in Barcelona, Spain. GALAXY is one of the largest and most comprehensive prospective studies of circulating tumor DNA (ctDNA) testing in resectable colorectal cancer (CRC). This latest analysis, which will also.

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced it will present new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, at the 2024 European Society for Medical Oncology (ESMO) Congress taking place Sept. 13-16 in Barcelona, Spain. Natera and its collaborators will present a total of nine abstracts, including five poster presentations from the GALAXY observational arm of.

Natera, Inc. is a diagnostic company focusing on cfDNA tests in women's health, organ health, and oncology. Natera's MRD test, Signatera, demonstrated strong growth, with a 64% increase in processed tests year-over-year, positioning it as the company's fastest-growing product. The liquid biopsy market is projected to grow at an 11% CAGR, with significant expansion in North America, supporting the long-term growth potential of Signatera.

The headline numbers for Natera (NTRA) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Natera (NTRA) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.97 per share a year ago.

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that its latest research and data on prenatal and reproductive genetics will be presented at the 28th International Conference on Prenatal Diagnosis and Therapy. Hosted by the International Society of Prenatal Diagnosis (ISPD), the conference will take place July 7-10, 2024, in Boston, MA. Below is the list of poster presentations that will be shared at the.